{
  "anticoagulants": {
    "doacs": {
      "apixaban": {
        "name": "Apixaban (Eliquis)",
        "mechanism": "Factor Xa inhibitor",
        "dosing": {
          "standard": "5mg PO BID",
          "reduced": "2.5mg PO BID if ≥2 criteria: age ≥80, weight ≤60kg, SCr ≥1.5mg/dL",
          "renal_adjustment": "Avoid if CrCl <15mL/min"
        },
        "advantages": [
          "Lowest bleeding risk among DOACs",
          "No food requirements",
          "BID dosing may improve compliance",
          "Effective in both valvular and non-valvular AF"
        ],
        "monitoring": [
          "Baseline: CBC, CMP, PT/PTT",
          "Follow-up: Renal function q6-12 months",
          "No routine coagulation monitoring needed"
        ],
        "reversal": "Andexanet alfa (preferred), 4-Factor PCC if unavailable",
        "drug_interactions": [
          "Strong CYP3A4 and P-gp inhibitors (reduce dose)",
          "Strong CYP3A4 and P-gp inducers (avoid concurrent use)"
        ],
        "clinical_pearls": [
          "Most studied DOAC with excellent safety profile",
          "First choice for most AF patients",
          "Lower GI bleeding risk compared to rivaroxaban"
        ]
      },
      "rivaroxaban": {
        "name": "Rivaroxaban (Xarelto)",
        "mechanism": "Factor Xa inhibitor",
        "dosing": {
          "standard": "20mg PO daily with food",
          "reduced": "15mg PO daily with food if CrCl 15-50mL/min",
          "renal_adjustment": "Avoid if CrCl <15mL/min"
        },
        "advantages": [
          "Once daily dosing",
          "Extensive clinical experience",
          "Good efficacy data"
        ],
        "requirements": [
          "MUST take with food to ensure absorption",
          "Crushing tablet acceptable if mixed with applesauce"
        ],
        "monitoring": "Same as apixaban",
        "reversal": "Andexanet alfa (preferred), 4-Factor PCC if unavailable",
        "disadvantages": [
          "Higher GI bleeding risk than apixaban",
          "Food requirement may affect adherence"
        ]
      },
      "dabigatran": {
        "name": "Dabigatran (Pradaxa)",
        "mechanism": "Direct thrombin inhibitor",
        "dosing": {
          "standard": "150mg PO BID",
          "reduced": "110mg PO BID if age ≥80, 75mg PO BID if CrCl 15-30mL/min",
          "renal_adjustment": "Avoid if CrCl <15mL/min"
        },
        "unique_features": [
          "Only reversible DOAC (idarucizumab - Praxbind)",
          "Direct thrombin inhibition vs Factor Xa"
        ],
        "disadvantages": [
          "Highest GI bleeding risk among DOACs",
          "BID dosing",
          "Dyspepsia in 5-10% patients",
          "Requires acidic environment (avoid PPI when possible)"
        ],
        "storage": "Keep in original bottle, discard after 30 days",
        "reversal": "Idarucizumab (Praxbind) - specific antidote"
      },
      "edoxaban": {
        "name": "Edoxaban (Savaysa)",
        "mechanism": "Factor Xa inhibitor",
        "dosing": {
          "standard": "60mg PO daily",
          "reduced": "30mg PO daily if CrCl 15-50mL/min, weight ≤60kg, or concomitant P-gp inhibitors"
        },
        "unique_contraindication": "CrCl >95mL/min (decreased efficacy)",
        "advantages": [
          "Once daily dosing",
          "No food requirement",
          "Good tolerability profile"
        ],
        "clinical_use": "Less commonly prescribed, good alternative if others not tolerated"
      }
    },
    "warfarin": {
      "name": "Warfarin (Coumadin)",
      "mechanism": "Vitamin K antagonist",
      "indications": [
        "Mechanical heart valve",
        "Moderate-severe mitral stenosis",
        "DOAC contraindicated/intolerant",
        "Cost considerations",
        "Dialysis patients"
      ],
      "dosing": {
        "initial": "5mg daily (2.5mg if elderly, high bleeding risk)",
        "target_inr": "2.0-3.0",
        "mechanical_valve": "2.5-3.5 depending on valve type/position"
      },
      "monitoring": {
        "initiation": "INR every 2-3 days x 1 week, then weekly x 3 weeks",
        "maintenance": "Monthly when stable, every 6 weeks maximum",
        "dose_adjustments": "Change weekly dose by 10-20%"
      },
      "drug_interactions": [
        "Antibiotics (especially quinolones, sulfonamides)",
        "Amiodarone (reduce warfarin dose 25-50%)",
        "NSAIDs, aspirin (increase bleeding risk)",
        "Numerous others - always check interactions"
      ],
      "dietary_considerations": [
        "Consistent vitamin K intake",
        "Green leafy vegetables in moderation",
        "Avoid cranberry juice, alcohol binges"
      ],
      "reversal": {
        "major_bleeding": "4-Factor PCC + Vitamin K 5-10mg IV",
        "urgent_surgery": "4-Factor PCC",
        "elevated_inr_no_bleeding": "Hold doses, Vitamin K 2.5-5mg PO"
      }
    }
  },
  "rate_control": {
    "beta_blockers": {
      "metoprolol": {
        "name": "Metoprolol",
        "formulations": {
          "immediate_release": "25-100mg PO BID",
          "extended_release": "25-200mg PO daily (succinate - preferred)"
        },
        "iv_dosing": "2.5-5mg IV q5min x3 (max 15mg)",
        "advantages": [
          "First-line for rate control",
          "Cardioprotective in CAD",
          "Mortality benefit in heart failure"
        ],
        "monitoring": "HR, BP, signs of heart failure",
        "contraindications": [
          "Severe bradycardia (<50 bpm)",
          "High-grade AV block",
          "Decompensated heart failure",
          "Severe COPD/asthma"
        ],
        "clinical_pearls": [
          "Use succinate form for heart failure",
          "Start low, titrate slowly",
          "Check for peripheral signs of poor perfusion"
        ]
      },
      "carvedilol": {
        "name": "Carvedilol (Coreg)",
        "dosing": "3.125-25mg PO BID",
        "unique_features": [
          "Alpha and beta blockade",
          "Preferred in heart failure",
          "Vasodilatory properties"
        ],
        "advantages": "Mortality benefit in heart failure, less bradycardia",
        "food_requirement": "Take with food to reduce orthostatic hypotension"
      }
    },
    "calcium_channel_blockers": {
      "diltiazem": {
        "name": "Diltiazem (Cardizem)",
        "formulations": {
          "immediate_release": "30-90mg PO QID",
          "extended_release": "120-360mg PO daily"
        },
        "iv_dosing": {
          "bolus": "0.25mg/kg IV over 2 min",
          "infusion": "5-15mg/hr continuous infusion"
        },
        "advantages": [
          "Excellent rate control",
          "Well tolerated",
          "Effective during exercise"
        ],
        "contraindications": [
          "EF <40%",
          "Hypotension",
          "Heart block",
          "Decompensated heart failure"
        ]
      },
      "verapamil": {
        "name": "Verapamil (Calan)",
        "dosing": "120-480mg daily (extended-release preferred)",
        "advantages": "Effective rate control, less negative inotropy than diltiazem",
        "disadvantages": "More constipation, drug interactions"
      }
    },
    "digoxin": {
      "name": "Digoxin (Lanoxin)",
      "mechanism": "Na+/K+-ATPase inhibitor, vagal stimulation",
      "indications": [
        "HFrEF with hypotension limiting other agents",
        "Combination therapy for rate control",
        "Sedentary patients (less effective during exercise)"
      ],
      "dosing": {
        "maintenance": "0.125-0.25mg PO daily",
        "elderly": "0.125mg daily or every other day",
        "renal_adjustment": "Reduce dose if CrCl <60mL/min"
      },
      "monitoring": {
        "baseline": "Renal function, electrolytes, ECG",
        "ongoing": "Digoxin level (target 0.5-2.0 ng/mL), K+, Mg2+",
        "toxicity": "N/V, visual changes, arrhythmias"
      },
      "drug_interactions": [
        "Amiodarone (reduce digoxin dose 50%)",
        "Verapamil/diltiazem (reduce digoxin dose 25%)",
        "Quinidine, macrolides"
      ],
      "contraindications": [
        "Heart block",
        "Hypertrophic cardiomyopathy",
        "WPW syndrome with AF"
      ]
    }
  },
  "antiarrhythmics": {
    "class_iii": {
      "amiodarone": {
        "name": "Amiodarone (Cordarone, Pacerone)",
        "indications": [
          "Most effective antiarrhythmic",
          "Structural heart disease acceptable",
          "Post-operative AF",
          "Hemodynamically unstable AF"
        ],
        "dosing": {
          "loading": "600-800mg PO daily x 2-4 weeks",
          "maintenance": "200mg PO daily (lowest effective dose)",
          "iv_acute": "150mg IV over 10min, then 1mg/min x 6h, then 0.5mg/min"
        },
        "monitoring": {
          "baseline": "PFT, TFT, LFT, ophthalmology exam, CXR, ECG",
          "ongoing": "Every 6 months - PFT, TFT, LFT, ophthalmology"
        },
        "toxicities": [
          "Pulmonary fibrosis (most serious - 5-10%)",
          "Thyroid dysfunction (hyper/hypothyroid - 10-20%)",
          "Hepatotoxicity (5-10%)",
          "Photosensitivity, blue-gray skin discoloration",
          "Corneal deposits (nearly universal, usually asymptomatic)"
        ],
        "drug_interactions": [
          "Warfarin (reduce dose 25-50%)",
          "Digoxin (reduce dose 50%)",
          "QT-prolonging drugs"
        ],
        "contraindications": [
          "Severe pulmonary disease",
          "Thyroid dysfunction",
          "Severe hepatic disease",
          "Iodine allergy (relative)"
        ]
      },
      "dofetilide": {
        "name": "Dofetilide (Tikosyn)",
        "indications": [
          "AF with heart failure",
          "Post-MI patients",
          "Renal dysfunction (renally cleared)"
        ],
        "requirements": "3-day inpatient initiation with continuous telemetry",
        "dosing": {
          "initial": "Based on CrCl: 500mcg BID (CrCl >60), 250mcg BID (CrCl 40-60), 125mcg BID (CrCl 20-40)",
          "adjustment": "Based on QTc measurements"
        },
        "monitoring": {
          "initiation": "QTc at 2-3 hours after each dose",
          "ongoing": "QTc, electrolytes, renal function"
        },
        "contraindications": [
          "QTc >440ms (men) or >460ms (women)",
          "CrCl <20mL/min",
          "Hypokalemia, hypomagnesemia"
        ]
      }
    },
    "class_ic": {
      "flecainide": {
        "name": "Flecainide (Tambocor)",
        "indications": "Structurally normal hearts only",
        "dosing": "50-150mg PO BID",
        "contraindications": [
          "CAD",
          "Structural heart disease",
          "Heart failure",
          "Bundle branch block",
          "CrCl <35mL/min"
        ],
        "monitoring": "ECG (QRS widening), electrolytes",
        "advantages": "Very effective for paroxysmal AF, well-tolerated in appropriate patients"
      },
      "propafenone": {
        "name": "Propafenone (Rythmol)",
        "indications": "Structurally normal hearts only",
        "dosing": "150-300mg PO TID",
        "contraindications": "Same as flecainide",
        "unique_features": "Mild beta-blocking properties"
      }
    }
  },
  "combination_strategies": {
    "rate_control_combinations": [
      "Beta-blocker + digoxin (especially in HFrEF)",
      "Beta-blocker + diltiazem (if inadequate rate control)",
      "Avoid: Beta-blocker + verapamil (excessive bradycardia risk)"
    ],
    "anticoagulation_antiplatelet": [
      "DOAC + aspirin 81mg (if CAD, increase bleeding risk)",
      "Triple therapy: DOAC + aspirin + clopidogrel (post-PCI, limit duration)",
      "Avoid: DOAC + dual antiplatelet therapy long-term"
    ]
  },
  "perioperative_management": {
    "elective_surgery": {
      "low_bleeding_risk": "Continue anticoagulation",
      "high_bleeding_risk": "Hold DOAC 24-48h pre-op, restart 12-24h post-op",
      "bridging": "Generally not needed for DOACs"
    },
    "urgent_surgery": {
      "recent_doac": "Delay surgery if possible, consider reversal agents",
      "time_since_dose": ">12h (apixaban/dabigatran), >24h (rivaroxaban/edoxaban)"
    }
  },
  "patient_counseling": {
    "anticoagulation": [
      "Bleeding precautions (soft toothbrush, electric razor)",
      "When to seek medical attention (unusual bleeding, severe headache)",
      "Medication adherence critical for stroke prevention",
      "No need for dietary restrictions with DOACs"
    ],
    "rate_control": [
      "Monitor pulse daily, report if <50 or >120 bpm",
      "Rise slowly to prevent dizziness",
      "Regular exercise as tolerated",
      "Report worsening shortness of breath or fatigue"
    ]
  }
}
